Lebrikizumab reduced interference of itch on sleep at 52 weeks in patients with moderate-to- severe atopic dermatitis: pooled analysis of two phase 3 randomized controlled trials

被引：0
|
作者：
Yosipovitch, Gil [1 ]
Lio, Peter A. [2 ]
Rosmarin, David [3 ]
Legat, Franz J. [4 ]
Carrascosa, Jose-Manuel [5 ]
Meskimen, Eric [6 ]
Casillas, Marta [6 ]
Pierce, Evangeline [6 ]
Xu, Chenjia [6 ]
Zhong, Jinglin [7 ]
Staender, Sonja [8 ]
机构：
[1] Univ Miami, Miller Sch Med, Coral Gables, FL USA
[2] Northwestern Univ, Feinberg Sch Med, Chicago, IL USA
[3] Tufts Univ, Sch Med, Boston, MA USA
[4] Med Univ Graz, Graz, Austria
[5] Hosp Badalona Germans Trias & Pujol, Barcelona, Spain
[6] Eli Lilly & Co, Indianapolis, IN USA
[7] IQVIA, Rockville, MD USA
[8] Univ Hosp Munster, Munster, Germany
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2023年 / 89卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
41916
引用
收藏
页码：AB61 / AB61
页数：1
相关论文
共 50 条
  • [1] Lebrikizumab improvement in itch reduction at 52 weeks in patients with moderate-to-severe atopic dermatitis: pooled analysis of two phase 3 randomized controlled trials
    Yosipovitch, Gil
    Lio, Peter
    Rosmarin, David
    Legat, Franz
    Carrascosa, Jose Manuel
    Meskimen, Eric
    Casillas, Marta
    Pierce, Evangeline
    Liu, Zhuqing
    Zhong, Jinglin
    Staender, Sonja
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB188 - AB188
  • [2] <show/>Lebrikizumab improved itch and reduced the extent of itch interference on sleep in patients with moderate-to-severe atopic dermatitis: two randomized, placebo-controlled, phase III trials<show/>
    Yosipovitch, Gil
    Lio, Peter A.
    Rosmarin, David
    Serra-Baldrich, Esther
    Legat, Franz J.
    Casillas, Marta
    Pierce, Evangeline
    Liu, Zhuqing
    Sun, Luna
    Elmaraghy, Hany
    Staender, Sonja
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 190 (02) : 289 - 291
  • [3] Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis
    Silverberg, Jonathan I.
    Guttman-Yassky, Emma
    Thaci, Diamant
    Irvine, Alan D.
    Gold, Linda Stein
    Blauvelt, Andrew
    Simpson, Eric L.
    Chu, Chia-Yu
    Liu, Zhuqing
    Lima, Renata Gontijo
    Pillai, Sreekumar G.
    Seneschal, Julien
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (12): : 1080 - 1091
  • [4] Lebrikizumab monotherapy improves quality of life through improvement in itch and sleep: Results from two Phase 3 trials in patients with moderate-to-severe atopic dermatitis
    Yosipovitch, Gil
    de Bruin-Weller, Marjolein
    Wiseman, Marni
    Elberling, Jesper
    Gutermuth, Jan
    Pierce, Evangeline
    Montmayeur, Sonia
    Ding, Yuxin
    Yang, Emily
    Chisolm, Sarah
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB61 - AB61
  • [5] EVOLUTION OF EASI RESPONSE WITH LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO- SEVERE ATOPIC DERMATITIS: POOLED RESULTS FROM TWO PHASE 3 TRIALS (ADVOCATE1 AND ADVOCATE2) AT WEEK 16
    Wollenberg, Andreas
    Warren, Richard B.
    Silverberg, Jonathan I.
    Guttman-Yassky, Emma
    Thaci, Diamant
    Irvine, Alan D.
    Gold, Linda Stein
    Blauvelt, Andrew
    Simpson, Eric L.
    Chu, Chia-Yu
    Liu, Zhuqing T.
    Lima, Renata Gontijo
    Pillai, Sreekumar
    Gil, Esther Garcia
    Seneschal, Julien
    ACTA DERMATO-VENEREOLOGICA, 2023, 103 : 53 - 53
  • [6] TAPINAROF CREAM IMPROVED ITCH IN TWO PHASE 3 TRIALS OF MODERATE TO SEVERE ATOPIC DERMATITIS
    Silverberg, J.
    Boguniewicz, M.
    Rubenstein, D.
    Tallman, A.
    Brown, P.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2023, 131 (05) : S90 - S90
  • [7] Stable Response and Sustained Improvement of Itch and Sleep Symptoms in Patients with Atopic Dermatitis Treated with Lebrikizumab over 52 Weeks
    Yosipovitch, Gil
    Lio, Peter
    Legat, Franz J.
    Chovatiya, Raj
    Deleuran, Mette
    Pierce, Evangeline
    Casillas, Marta
    Ding, Yuxin
    Yang, Fan E.
    Bardolet, Laia
    Staender, Sonja
    DERMATOLOGY AND THERAPY, 2024, 14 (08) : 2171 - 2180
  • [8] 497-Lebrikizumab in combination with topical corticosteroids maintains improvements in itch and sleep at 68 weeks in patients with moderate-to-severe atopic dermatitis
    Yosipovitch, Gil
    Lio, Peter A.
    Rosmarin, David
    Casillas, Marta
    Yang, Fan Emily
    Hu, Chaoran
    Pierce, Evangeline
    Legat, Franz J.
    Carrascosa, Jose-Manuel
    Crane, Heidi
    Boncompte, Laia
    Stander, Sonja
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 190 : II6 - II7
  • [9] Improved quality of life in patients treated with lebrikizumab monotherapy is mediated by improvements in itch and sleep: results from two phase III trials in patients with moderate-to-severe atopic dermatitis
    Yosipovitch, Gil
    de Bruin-Weller, Marjolein
    Wiseman, Marni
    Elberling, Jesper
    Gutermuth, Jan
    Pierce, Evangeline
    Montmayeur, Sonia
    Yang, Fan Emily
    Ding, Yuxin
    Bardolet, Laia
    Chisolm, Sarah
    CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2025,
  • [10] Efficacy of lebrikizumab in adults and adolescents with moderate-to-severe atopic dermatitis by age of onset: analysis of two phase 3 clinical trials
    Zirwas, Matthew J.
    Boguniewicz, Mark
    Rosmarin, David
    Fuxench, Zelma Chiesa
    Warren, Richard B.
    Torres, Tiago
    de Bruin-Weller, Marjolein
    Dawson, Zach
    Atwater, Amber Reck
    Elmaraghy, Hany
    Pierce, Evangeline
    Bardolet, Laia
    Zhong, Jinglin
    Armstrong, April W.
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 191 : 54 - 56
12345